Patents by Inventor Fushi Wen
Fushi Wen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250092470Abstract: Provided herein are methods for detecting and discriminating bacteria and fungal species by nucleic acid amplification, then hybridization analysis on a microarray. Primer pairs are used to simultaneously amplify multiple ribosomal Hypervariable regions from the rDNA or rRNA in bacteria and/or fungi as a multiplex amplification reaction, wherein the resulting hypervariable region amplicon mix is analyzed by hybridization to nucleic acid probes that are complementary to unique sequence determinants within those amplified hypervariable regions. The combination of multiplex amplification and microarray hybridization is used for detection and differentiation of specific species within a microbial set relevant to human or animal health or environmental or agricultural analysis, based on simultaneous analysis of the sequence in two or more hypervariable regions, concurrently.Type: ApplicationFiled: September 20, 2024Publication date: March 20, 2025Applicant: PathogenDx, Inc.Inventors: Michael E. Hogan, Frederick H. Eggers, Melissa R. May, Fushi Wen, Kevin O'Brien, Benjamin A. Katchman
-
Publication number: 20240384359Abstract: Provided herein are methods for identifying antibiotic resistance in a subject in need thereof and for detecting drug resistance in a blood-borne pathogenic bacteria. The methods amplify RNA isolated from whole blood in a multiplexed, isothermal nucleic acid sequence-based amplification (NASBA) reaction using at least one isothermal primer pair with nucleotide sequences specific to a drug resistance marker and with a labeled detector probe binding site and a T7 promoter sequence. Amplicons are hybridized to drug resistance marker probes and to a labeled universal detector probe. A signal indicates drug resistance in the blood-borne pathogenic bacteria.Type: ApplicationFiled: August 5, 2024Publication date: November 21, 2024Applicant: PathogenDx, Inc.Inventors: Michael E. Hogan, Fushi Wen, Frederick H. Eggers
-
Patent number: 12054794Abstract: Provided herein is a method for detecting the presence of a COVID-19 virus RNA or other pathogenic respiratory viruses, such as an influenza virus, or other RNA of interest in a sample. Nucleic acids are obtained from the sample and are used as a template in a combined isothermal reverse transcription, RNAse H and isothermal amplification reaction to generate single stranded RNA amplicons containing sequences complementary to fluorescent labeled detector probes. The single-stranded RNA amplicons hybridize to the detector probe and to hybridization probes with sequences complementary to a sequence determinant in the COVID-19 or other virus RNAs. The microarray is imaged to detect fluorescent signals thereby identifying the virus.Type: GrantFiled: June 15, 2022Date of Patent: August 6, 2024Inventors: Fushi Wen, Frederick H. Eggers, Michael E. Hogan
-
Patent number: 11920188Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant. Also provided is a method of distinguishing each clade variant from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: GrantFiled: May 27, 2021Date of Patent: March 5, 2024Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Patent number: 11702709Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant and each clade variant is distinguished from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: GrantFiled: November 18, 2021Date of Patent: July 18, 2023Assignee: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Publication number: 20220403476Abstract: Provided herein is a method for detecting the presence of a COVID-19 virus RNA or other pathogenic respiratory viruses, such as an influenza virus, or other RNA of interest in a sample. Nucleic acids are obtained from the sample and are used as a template in a combined isothermal reverse transcription, RNAse H and isothermal amplification reaction to generate single stranded RNA amplicons containing sequences complementary to fluorescent labeled detector probes. The single-stranded RNA amplicons hybridize to the detector probe and to hybridization probes with sequences complementary to a sequence determinant in the COVID-19 or other virus RNAs. The microarray is imaged to detect fluorescent signals thereby identifying the virus.Type: ApplicationFiled: June 15, 2022Publication date: December 22, 2022Applicant: PathogenDx, Inc.Inventors: Fushi Wen, Frederick H. Eggers, Michael E. Hogan
-
Publication number: 20220267829Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant and each clade variant is distinguished from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants. Also provided are methods for detecting and genotyping SARS-CoV-2.Type: ApplicationFiled: February 22, 2022Publication date: August 25, 2022Applicant: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Publication number: 20220267867Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant and each clade variant is distinguished from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: ApplicationFiled: November 18, 2021Publication date: August 25, 2022Applicant: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Publication number: 20220251635Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant. Also provided is a method of distinguishing each clade variant from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: ApplicationFiled: May 27, 2021Publication date: August 11, 2022Applicant: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan